Még nem toboroz
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459· 2. fázis· The Lymphoma Academic Research Organisation· Forrás
Még nem toboroz
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
2026-525763-40-00· 2. fázis· French Innovative Leukemia Organization (F.I.L.O.).· Forrás
Még nem toboroz
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· 3. fázis· Fondation A De Rothschild· Forrás
Toboroz
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
NCT07189325· 3. fázis· University Hospital, Montpellier· Forrás
Toboroz
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711· 3. fázis· Pfizer· Forrás
Toboroz
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis
2024-511458-32-00· 3. fázis· Alfasigma S.p.A.· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Még nem toboroz
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
NCT06663189· 3. fázis· University Hospital, Strasbourg, France· Forrás
Toboroz
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Fut, nem toboroz
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2024-510965-41-00· 3. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Fut, nem toboroz
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-508235-31-00· 3. fázis· Almirall S.A.· Forrás
Toboroz
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994· 3. fázis· InnoCare Pharma Inc.· Forrás
Fut, nem toboroz
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
NCT05782127· 1/2. fázis· Groupe Francophone des Myelodysplasies· Forrás
Fut, nem toboroz
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
NCT04974216· 2. fázis· The Lymphoma Academic Research Organisation· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
MInimal Residual Disease Adapted Strategy
NCT04934475· 3. fázis· Intergroupe Francophone du Myelome· Forrás
Fut, nem toboroz
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
NCT03653273· 3. fázis· Rennes University Hospital· Forrás
Fut, nem toboroz
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT03799835· 3. fázis· UNICANCER· Forrás
Lezárult
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
NCT02980510· 2. fázis· UNICANCER· Forrás